UGN-101: Consistent Complete Response (CR) Rate of 59 Percent in Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Durability of Response Determined to be 89 Percent at Six Months and 84 Percent at 12 Months Rolling NDA Submission on Track for Q4 2019 with Planned Launch in
Company to Also Participate in September Investor Conferences NEW YORK --(BUSINESS WIRE)--Sep. 10, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will host an Investor Day on
NEW YORK --(BUSINESS WIRE)--Sep. 6, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced the grants of inducement restricted stock units (“RSUs”) to 15 new employees in connection with their
UGN-101 Rolling NDA Submission on Track for Q4 2019 with Planned Launch in 1H 2020 Final Topline UGN-101 Phase 3 Data from OLYMPUS Trial to be Announced in Q3 2019 Company Investor Day Scheduled for September 24, 2019 Quarterly Conference Call and Webcast to be Held on Monday, August 12, 2019 at
Conference Call and Webcast Scheduled for Monday, August 12, 2019 at 8:30 AM ET NEW YORK --(BUSINESS WIRE)--Aug. 5, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report second quarter 2019 financial results on Friday, August 9, 2019 , prior to the open of the market.
NEW YORK --(BUSINESS WIRE)--Jul. 1, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it joined the broad-market Russell 3000 ® Index at the conclusion of the 2019 Russell indexes
NEW YORK --(BUSINESS WIRE)--May 30, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at three investor conferences in June: Jefferies 2019 Global Healthcare Conference Tuesday, June 4th 9:00AM Eastern Time New York, NY Goldman Sachs 40 th Annual Global
Recent Data Presentation Highlights Consistent Complete Response Rate and Strong Durability at Six-Months in Evaluable Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Completion of UGN-101 Rolling NDA Submission to the FDA On Track for 2H 2019 Pre-Commercial Activities and
Complete Response (CR) Rate Consistent at 59 Percent Six-month Durability Strong with 89 Percent of Evaluable Patients Remaining in CR Full Phase 3 Data Anticipated for 2H 2019 NEW YORK --(BUSINESS WIRE)--May 5, 2019-- UroGen Pharma Ltd. (Nasdaq: URGN), a clinical-stage biopharmaceutical company
Conference Call and Webcast Scheduled for 8:30 AM ET NEW YORK --(BUSINESS WIRE)--May 2, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report first quarter 2019 financial results on Thursday, May 9, 2019 , prior to the open of the market.
